ALZCHEM GROUP AG (ACT.DE) Stock Fundamental Analysis
Europe • Frankfurt Stock Exchange • FRA:ACT • DE000A2YNT30
154.6 EUR
-2.8 (-1.78%)
Last: Jan 30, 2026, 07:00 PM
Overall ACT gets a fundamental rating of 7 out of 10. We evaluated ACT against 71 industry peers in the Chemicals industry. Both the health and profitability get an excellent rating, making ACT a very profitable company, without any liquidiy or solvency issues. ACT is valied quite expensively at the moment, while it does show a decent growth rate. These ratings would make ACT suitable for quality investing!
1. Profitability
1.1 Basic Checks
- ACT had positive earnings in the past year.
- In the past year ACT had a positive cash flow from operations.
- In the past 5 years ACT has always been profitable.
- Of the past 5 years ACT 4 years had a positive operating cash flow.
1.2 Ratios
- Looking at the Return On Assets, with a value of 10.49%, ACT belongs to the top of the industry, outperforming 94.37% of the companies in the same industry.
- ACT has a Return On Equity of 26.47%. This is amongst the best in the industry. ACT outperforms 94.37% of its industry peers.
- ACT has a Return On Invested Capital of 13.45%. This is amongst the best in the industry. ACT outperforms 91.55% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for ACT is above the industry average of 7.19%.
- The last Return On Invested Capital (13.45%) for ACT is above the 3 year average (12.06%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 10.49% | ||
| ROE | 26.47% | ||
| ROIC | 13.45% |
ROA(3y)8.81%
ROA(5y)7.86%
ROE(3y)22.87%
ROE(5y)25.91%
ROIC(3y)12.06%
ROIC(5y)10.63%
1.3 Margins
- ACT has a Profit Margin of 10.97%. This is amongst the best in the industry. ACT outperforms 81.69% of its industry peers.
- ACT's Profit Margin has improved in the last couple of years.
- ACT has a better Operating Margin (15.93%) than 83.10% of its industry peers.
- ACT's Operating Margin has improved in the last couple of years.
- ACT's Gross Margin of 66.55% is amongst the best of the industry. ACT outperforms 97.18% of its industry peers.
- In the last couple of years the Gross Margin of ACT has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 15.93% | ||
| PM (TTM) | 10.97% | ||
| GM | 66.55% |
OM growth 3Y17.53%
OM growth 5Y12.4%
PM growth 3Y14.29%
PM growth 5Y15.31%
GM growth 3Y2.01%
GM growth 5Y1.44%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), ACT is creating value.
- The number of shares outstanding for ACT has been reduced compared to 1 year ago.
- ACT has less shares outstanding than it did 5 years ago.
- The debt/assets ratio for ACT has been reduced compared to a year ago.
2.2 Solvency
- ACT has an Altman-Z score of 5.08. This indicates that ACT is financially healthy and has little risk of bankruptcy at the moment.
- The Altman-Z score of ACT (5.08) is better than 88.73% of its industry peers.
- The Debt to FCF ratio of ACT is 1.32, which is an excellent value as it means it would take ACT, only 1.32 years of fcf income to pay off all of its debts.
- ACT has a Debt to FCF ratio of 1.32. This is amongst the best in the industry. ACT outperforms 94.37% of its industry peers.
- ACT has a Debt/Equity ratio of 0.16. This is a healthy value indicating a solid balance between debt and equity.
- Looking at the Debt to Equity ratio, with a value of 0.16, ACT is in the better half of the industry, outperforming 73.24% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.16 | ||
| Debt/FCF | 1.32 | ||
| Altman-Z | 5.08 |
ROIC/WACC1.85
WACC7.29%
2.3 Liquidity
- ACT has a Current Ratio of 2.87. This indicates that ACT is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Current ratio, with a value of 2.87, ACT belongs to the top of the industry, outperforming 83.10% of the companies in the same industry.
- A Quick Ratio of 1.77 indicates that ACT should not have too much problems paying its short term obligations.
- With an excellent Quick ratio value of 1.77, ACT belongs to the best of the industry, outperforming 81.69% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.87 | ||
| Quick Ratio | 1.77 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 24.12% over the past year.
- The Earnings Per Share has been growing by 24.60% on average over the past years. This is a very strong growth
- Looking at the last year, ACT shows a small growth in Revenue. The Revenue has grown by 1.05% in the last year.
- Measured over the past years, ACT shows a quite strong growth in Revenue. The Revenue has been growing by 8.06% on average per year.
EPS 1Y (TTM)24.12%
EPS 3Y25.02%
EPS 5Y24.6%
EPS Q2Q%31.66%
Revenue 1Y (TTM)1.05%
Revenue growth 3Y9.49%
Revenue growth 5Y8.06%
Sales Q2Q%6.46%
3.2 Future
- ACT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.26% yearly.
- Based on estimates for the next years, ACT will show a small growth in Revenue. The Revenue will grow by 6.02% on average per year.
EPS Next Y21.07%
EPS Next 2Y12.7%
EPS Next 3Y18.06%
EPS Next 5Y20.26%
Revenue Next Year2.51%
Revenue Next 2Y5.13%
Revenue Next 3Y8.61%
Revenue Next 5Y6.02%
3.3 Evolution
- The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 25.34 indicates a quite expensive valuation of ACT.
- ACT's Price/Earnings ratio is in line with the industry average.
- The average S&P500 Price/Earnings ratio is at 28.30. ACT is around the same levels.
- With a Price/Forward Earnings ratio of 23.89, ACT is valued on the expensive side.
- The rest of the industry has a similar Price/Forward Earnings ratio as ACT.
- The average S&P500 Price/Forward Earnings ratio is at 25.57. ACT is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.34 | ||
| Fwd PE | 23.89 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, ACT is valued a bit more expensive than 60.56% of the companies in the same industry.
- The rest of the industry has a similar Price/Free Cash Flow ratio as ACT.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 44.98 | ||
| EV/EBITDA | 13.51 |
4.3 Compensation for Growth
- ACT's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
- ACT has an outstanding profitability rating, which may justify a higher PE ratio.
- ACT's earnings are expected to grow with 18.06% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.2
PEG (5Y)1.03
EPS Next 2Y12.7%
EPS Next 3Y18.06%
5. Dividend
5.1 Amount
- ACT has a Yearly Dividend Yield of 1.16%. Purely for dividend investing, there may be better candidates out there.
- ACT's Dividend Yield is slightly below the industry average, which is at 2.45.
- Compared to the average S&P500 Dividend Yield of 1.82, ACT is paying slightly less dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.16% |
5.2 History
- The dividend of ACT has a limited annual growth rate of 6.00%.
Dividend Growth(5Y)6%
Div Incr Years5
Div Non Decr Years5
5.3 Sustainability
- 49.16% of the earnings are spent on dividend by ACT. This is a bit on the high side, but may be sustainable.
- The dividend of ACT is growing, but earnings are growing more, so the dividend growth is sustainable.
DP49.16%
EPS Next 2Y12.7%
EPS Next 3Y18.06%
ALZCHEM GROUP AG / ACT.DE FAQ
Can you provide the ChartMill fundamental rating for ALZCHEM GROUP AG?
ChartMill assigns a fundamental rating of 7 / 10 to ACT.DE.
What is the valuation status for ACT stock?
ChartMill assigns a valuation rating of 3 / 10 to ALZCHEM GROUP AG (ACT.DE). This can be considered as Overvalued.
Can you provide the profitability details for ALZCHEM GROUP AG?
ALZCHEM GROUP AG (ACT.DE) has a profitability rating of 9 / 10.
Can you provide the financial health for ACT stock?
The financial health rating of ALZCHEM GROUP AG (ACT.DE) is 9 / 10.
What is the earnings growth outlook for ALZCHEM GROUP AG?
The Earnings per Share (EPS) of ALZCHEM GROUP AG (ACT.DE) is expected to grow by 21.07% in the next year.